Curis vs Ocugen
CRIS and OCGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and OCGN compare
Ocugen is the larger company, worth 302 times as much as Curis ($281M against $930K).
Curis scores higher on the StockData Score (5 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | OCGN |
|---|---|---|
| Size and price | ||
| Market cap | $930K | $281M |
| Share price | $0.445 | $0.828 |
| Change, 1 year | −98.2% | −38.2% |
| Change, 5 years | −100.0% | −89.3% |
| Beta (5Y) | 1.90 | 1.65 |
| Employees | 24 | 116 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | – |
| FCF yield | – | −22.8% |
| Growth | ||
| Revenue growth, 5Y average | −2.7% | 152% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −6.8× |
| Current ratio | 0.43 | 0.77 (better) |
| Altman Z-score | −98.36 | −6.98 (better) |
| Piotroski F-score | 3 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.1% | 42.8% |
| Held by insiders | 20.4% | 2.4% |
| Insider net buying, 12 months | $5.5K (better) | −$1.1M |
| Short interest, % of float | 61.8% | 32.5% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.